untitled design

Modern respiratory virus vaccine approved in the USA

The U.S. Food and Drug Administration (FDA) has approved Moderna's respiratory syncytial virus (RSV) vaccine, the company announced Friday, opening up a chance to get a much-needed new prescription with a second product.

Moderna's vaccine has been approved by the FDA for the prevention of RSV-associated lower respiratory tract disease in adults ages 60 and older.

The company had previously said its vaccine could be used to treat acute respiratory illness associated with RSV as well as lower respiratory tract illness, and its shares fell more than 4%.

RSV, which produces cold-like symptoms but can be fatal to young children and older adults, causes about 14,000 deaths a year in adults ages 65 and older.

The Cambridge, Massachusetts-based company has been betting on experimental vaccines to offset the drop in demand for Covid-19 vaccines, its only commercialized product.

Moderna's RSV vaccine is the first non-Covid-19 messenger RNA (mRNA) vaccine to be approved in the United States. It will be sold under the trade name mRESVIA.

The company said mRNA vaccines, which teach the body to produce specific proteins that the immune system can recognize and attack, have the potential to treat multiple diseases and be more effective than conventional vaccines.

“The FDA’s approval of our second product, mRESVIA, builds on the strength and versatility of our mRNA platform,” Moderna CEO Stephane Bancel said in a statement.

Analysts, on average, forecast sales of Moderna's RSV vaccine of $340 million in 2024, growing to $830.5 million next year, according to LSEG data.

A panel of advisors from the US Centers for Disease Control and Prevention (CDC) will deliberate next month on recommendations for the vaccine's use and target population.

Moderna says it expects the vaccine to be available to eligible patients in the U.S. by the fall vaccination season.

Source: CNN Brasil

You may also like

Get the latest

Stay Informed: Get the Latest Updates and Insights


Most popular